Shanghai Haohai Biological Technology (HKG:6826, SHA:688366) recorded a 1% rise in attributable profit for the year 2024 to 420.4 million yuan from 416.1 million yuan a year prior, a March 21 filing with the Hong Kong bourse said.
Earnings per share were 1.80 yuan in the year, up from 1.75 yuan in the last fiscal year.
Revenue rose by 1.7% to 2.68 billion yuan in the period from 2.63 billion yuan a year prior.
The ophthalmic products manufacturer attributed the higher profit mainly to a rise in operating revenue.
The firm proposed a final dividend of 0.60 yuan per share for the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.